NASDAQ · Medical - Devices

LAB (LAB) Stock

$0.87 -3.27% NASDAQ: LAB Healthcare

Valuation

MetricValue
Price$0.87
Market Cap$339.79M
P/E Ratio-5.30
P/B Ratio0.98
P/S Ratio4.73
EPS (TTM)$-0.20
52-Week High$1.72
52-Week Low$0.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-17.69%
ROA-13.20%
ROCE-21.88%
Gross Margin-110.59%
Operating Margin-109.41%
Net Margin-1.09%
Debt/Equity0.05
Current Ratio4.20

Annual Financials (USD)

Metric20212022202320242025
Revenue$131.0M$98.0M$106.0M$174.0M$85.0M
Operating Profit$-67.0M$-116.0M$-77.0M$-175.0M$-93.0M
Net Profit$-59.0M$-190.0M$-75.0M$-139.0M$-75.0M
EPS$-0.78$-2.43$-0.94$-0.52$-0.20
Op Margin-51.7%-118.6%-72.0%-100.5%-109.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$275.0M$390.0M$323.0M$612.0M$568.0M
Total Liabilities$181.0M$472.0M$471.0M$141.0M$143.0M
Cash$28.0M$81.0M$52.0M$167.0M$118.0M
Borrowings$112.0M$103.0M$98.0M$33.0M$31.0M

Latest News

Stealthy startup Treeline plans a reverse merger BioPharma Dive · Jun 9, 2026 Standard BioTools, Treeline Biosciences to Merge in All-Stock Deal MT Newswires · Jun 8, 2026 Standard BioTools and Treeline Biosciences Announce Merger Agreement GlobeNewswire · Jun 8, 2026 Standard BioTools Regains Compliance With Nasdaq's Minimum Bid Price Requirement MT Newswires · Jun 8, 2026 Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates Zacks · May 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-44.0M$-89.0M$-43.0M$-143.0M$-74.0M
Investing Cash Flow$-25.0M$-92.0M$17.0M$355.0M$16.0M
Financing Cash Flow$6.0M$213.0M$-5.0M$-39.0M$0
Net Cash Flow$-40.0M$53.0M$-30.0M$116.0M$-48.0M
Free Cash Flow$-57.0M$-93.0M$-46.0M$-152.0M$-83.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-23.16%
Quick Ratio11.92
Interest Coverage—
Return 1Y-39.63%
Return 3Y-63.07%
Return 5Y-85.19%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADCTADC Therapeutics S.A. $1.19 +3.48% -1.09 $151.36M 0.00%
AVNS $24.99 +0.04% 19.96 $1.17B 0.00%
BVS $13.12 -0.68% 20.85 $888.85M 0.00%
CBLL $18.81 +3.07% -11.62 $713.70M 0.00%
CGEM $17.21 -1.49% -3.76 $1.06B 0.00%

About LAB

LAB is led by CEO Michael Egholm, publicly traded since 2011.

LAB stock trades at $0.87 with a market capitalization of $339.79M. The stock is valued at a price-to-earnings (P/E) ratio of -5.30, price-to-book of 0.98, price-to-sales of 4.73. Over the past 52 weeks the stock has ranged between $0.72 and $1.72, and currently trades 49.4% below its 52-week high.

On profitability, LAB generates a return on equity (ROE) of -17.69%, return on capital employed of -21.88%, an operating margin of -109.41%, a net profit margin of -1.09%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides